Further progress in Phase I/IIa PROTECT trial

AI SummaryClose X

Allergy Therapeutics announced positive progress in its Phase I/IIa PROTECT trial for its peanut allergy vaccine candidate, VLP Peanut. Dosing has been completed in healthy volunteers, with VLP Peanut being well-tolerated up to the highest planned dose. The final cohort of peanut allergic patients is progressing as planned, showing a supportive safety and tolerability profile. Encouraging dose-dependent biomarker responses and consistent safety data will inform Phase IIb dose selection. A total of 48 subjects have been enrolled and investigated during the trial. Earlier analysis suggested VLP Peanut is driving a reduction in allergic response, with a protective dose-dependent inhibition of Ara h2 IgE binding to B cells observed compared to placebo. The Phase IIb trial is expected to commence in H2 2026.

Disclaimer*

UK 100

Latest directors dealings